Flow Diverter Devices in the Treatment of Anterior Communicating Artery Region Aneurysms: Would the Regional Anatomy and the Aneurysm Location Affect the Outcomes?
anterior communicating artery
brain aneurysm
endovascular treatment
flow diverter
Journal
Brain sciences
ISSN: 2076-3425
Titre abrégé: Brain Sci
Pays: Switzerland
ID NLM: 101598646
Informations de publication
Date de publication:
10 Nov 2022
10 Nov 2022
Historique:
received:
12
10
2022
revised:
31
10
2022
accepted:
07
11
2022
entrez:
11
11
2022
pubmed:
12
11
2022
medline:
12
11
2022
Statut:
epublish
Résumé
In this study, the authors evaluated the efficacy and the safety of flow diverter devices (FDD) in anterior communicating artery (ACoA) region aneurysms, focusing on anatomical factors that could affect the outcome, such as the location of the aneurysm along the ACoA (centered on ACoA or decentered on the A1-A2 junction) and the anatomy of the ACoA region. Clinical, procedural and follow-up data were analyzed. Aneurysms were classified according to the location along the ACoA (centered or decentered on the A1-A2 junction) and on the basis of the anatomical configuration of the ACoA region. Safety was assessed by recording intraprocedural, periprocedural and delayed complications to determine the morbidity and mortality rates. The functional outcome was evaluated with the modified Rankin scale (mRS) prior to and after the endovascular procedure. To assess the efficacy, midterm and long-term clinical, angiographic and cross-sectional imaging follow-ups were recorded. Subgroup analysis according to the different ACoA regional anatomical configurations and the ACoA aneurysm locations were performed. 33 patients (17 males; 16 females) with ACoA region aneurysms were treated with FDDs. 27 aneurysms were located at the A1-A2 junction (82%) while the remaining six aneurysms were centered on the ACoA. No mortality was recorded. The overall morbidity rate was 6% (2/33 procedures). Major complications occurred in 33% (2/6) of ACoA aneurysms and in the 0% of A1-A2 junction aneurysms. Mid-term and long-term neuroimaging follow-ups showed the occlusion of the aneurysm in 28/33 cases (85%). Complete occlusion rates were 93% in the A1-A2 junction aneurysms and 50% in ACoA aneurysms. The FDD is a safe and effective tool that can be used in the treatment of selected cases of ACoA region aneurysms. The location of the aneurysm along the ACoA and the regional anatomy of the ACoA complex could affect the efficacy and safety.
Sections du résumé
BACKGROUND
BACKGROUND
In this study, the authors evaluated the efficacy and the safety of flow diverter devices (FDD) in anterior communicating artery (ACoA) region aneurysms, focusing on anatomical factors that could affect the outcome, such as the location of the aneurysm along the ACoA (centered on ACoA or decentered on the A1-A2 junction) and the anatomy of the ACoA region.
METHODS
METHODS
Clinical, procedural and follow-up data were analyzed. Aneurysms were classified according to the location along the ACoA (centered or decentered on the A1-A2 junction) and on the basis of the anatomical configuration of the ACoA region. Safety was assessed by recording intraprocedural, periprocedural and delayed complications to determine the morbidity and mortality rates. The functional outcome was evaluated with the modified Rankin scale (mRS) prior to and after the endovascular procedure. To assess the efficacy, midterm and long-term clinical, angiographic and cross-sectional imaging follow-ups were recorded. Subgroup analysis according to the different ACoA regional anatomical configurations and the ACoA aneurysm locations were performed.
RESULTS
RESULTS
33 patients (17 males; 16 females) with ACoA region aneurysms were treated with FDDs. 27 aneurysms were located at the A1-A2 junction (82%) while the remaining six aneurysms were centered on the ACoA. No mortality was recorded. The overall morbidity rate was 6% (2/33 procedures). Major complications occurred in 33% (2/6) of ACoA aneurysms and in the 0% of A1-A2 junction aneurysms. Mid-term and long-term neuroimaging follow-ups showed the occlusion of the aneurysm in 28/33 cases (85%). Complete occlusion rates were 93% in the A1-A2 junction aneurysms and 50% in ACoA aneurysms.
CONCLUSIONS
CONCLUSIONS
The FDD is a safe and effective tool that can be used in the treatment of selected cases of ACoA region aneurysms. The location of the aneurysm along the ACoA and the regional anatomy of the ACoA complex could affect the efficacy and safety.
Identifiants
pubmed: 36358450
pii: brainsci12111524
doi: 10.3390/brainsci12111524
pmc: PMC9688233
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Stroke. 2003 Jun;34(6):1398-403
pubmed: 12775880
Front Neurol. 2020 Sep 08;11:1020
pubmed: 33013671
Neurosurg Rev. 2021 Jun;44(3):1703-1712
pubmed: 32803404
Lancet. 2005 Sep 3-9;366(9488):809-17
pubmed: 16139655
J Neurosurg. 2016 Jul;125(1):120-7
pubmed: 26654182
Pol J Radiol. 2016 Aug 09;81:374-9
pubmed: 27559426
AJNR Am J Neuroradiol. 2017 Jun;38(6):1151-1155
pubmed: 28450432
J Neurointerv Surg. 2019 Jan;11(1):49-56
pubmed: 29871991
J Neurosurg Sci. 2021 Jun;65(3):361-368
pubmed: 33879762
J Neurosurg. 2018 Apr;128(4):1037-1043
pubmed: 28387623
Acta Neurol Belg. 2020 Feb;120(1):123-132
pubmed: 31745846
AJNR Am J Neuroradiol. 2019 Mar;40(3):497-502
pubmed: 30765379
J Neurosurg. 2013 Feb;118(2):408-16
pubmed: 23176329
J Neurointerv Surg. 2017 Jul;9(7):679-685
pubmed: 28130501
AJNR Am J Neuroradiol. 2014 Aug;35(8):1551-5
pubmed: 24948501
J Neurointerv Surg. 2019 Dec;11(12):1227-1234
pubmed: 31088939
AJNR Am J Neuroradiol. 2019 Apr;40(4):687-693
pubmed: 30872418
J Neurosurg. 2019 May 10;:1-8
pubmed: 31075778
Neurosurgery. 2016 Jul;79(1):14-22
pubmed: 26579967
Neurosurgery. 2004 May;54(5):1089-97; discussion 1097-8
pubmed: 15113462
AJNR Am J Neuroradiol. 2021 Aug;42(8):1479-1485
pubmed: 34117022
Interv Neuroradiol. 2018 Jun;24(3):237-245
pubmed: 29466903
Stroke. 2013 May;44(5):1343-7
pubmed: 23598522
Neurosurgery. 2020 Jan 1;86(Suppl 1):S13-S19
pubmed: 31838528
AJNR Am J Neuroradiol. 2014 May;35(5):943-7
pubmed: 24287090
Lancet Neurol. 2014 Apr;13(4):393-404
pubmed: 24646873
Clin Neuroradiol. 2017 Mar;27(1):51-56
pubmed: 26250557
J Neurointerv Surg. 2019 Nov;11(11):1118-1122
pubmed: 30975737